Cite
Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma
MLA
Best, Timothy, et al. “Variants at 6q21 Implicate PRDM1 in the Etiology of Therapy-Induced Second Malignancies after Hodgkin’s Lymphoma.” Nature Medicine, vol. 17, no. 8, Aug. 2011, p. 941. EBSCOhost, https://doi.org/10.1038/nm.2407.
APA
Best, T., Li, D., Skol, A. D., Kirchhoff, T., Jackson, S. A., Yasui, Y., Bhatia, S., Strong, L. C., Domchek, S. M., Nathanson, K. L., Olopade, O. I., Huang, R. S., Mack, T. M., Conti, D. V., Offit, K., Cozen, W., Robison, L. L., & Onel, K. (2011). Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin’s lymphoma. Nature Medicine, 17(8), 941. https://doi.org/10.1038/nm.2407
Chicago
Best, Timothy, Dalin Li, Andrew D. Skol, Tomas Kirchhoff, Sarah A. Jackson, Yutaka Yasui, Smita Bhatia, et al. 2011. “Variants at 6q21 Implicate PRDM1 in the Etiology of Therapy-Induced Second Malignancies after Hodgkin’s Lymphoma.” Nature Medicine 17 (8): 941. doi:10.1038/nm.2407.